Resultados de la búsqueda 201-210 of 9140 for N-Acetyl Selank

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  2. Enfermedad de Alzheimer

    Los investigadores de Mayo Clinic estudian la enfermedad de Alzheimer, mild cognitive impairmenty otras afecciones que afectan la memoria y el pensamiento.

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this trial is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of ...

  5. Cirugía - Ensayos clínicos - Mayo Clinic

    This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma ...

  6. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with ...

  7. Cirugía - Ensayos clínicos - Mayo Clinic

    Patients undergoing spine lumbar surgery will be asked to perform short exams/questionnaires aimed at determining cognitive function, quality of life, health ...

  8. Cirugía - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic ...

  9. Diagnósticos y tratamientos - Mayo Clinic

    AATD-specific treatment replaces missing AAT protein through infusions. Standard COPD therapy includes medicines, oxygen therapy and pulmonary rehabilitation.

  10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...